Last reviewed · How we verify
NCT03140826: ASARI II
Amplification and Selection of Antimicrobial Resistance in the Intestine II
trial testing meropenem in Antibiotic Selection Pressure in 60 participants. Completed in 31 July 2020.
31 July 2020
Quick facts
| Lead sponsor | University Hospital Tuebingen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 30 January 2018 |
| Primary completion | 31 July 2020 |
| Estimated completion | 31 July 2020 |
| Sites | 2 locations across Germany |
Drugs / interventions tested
- meropenem (Meropenem) — full drug profile →
Conditions studied
- Antibiotic Selection Pressure — all drugs for Antibiotic Selection Pressure →
Sponsor
University Hospital Tuebingen
Who can join
18 and older, any sex, with Antibiotic Selection Pressure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stool samples will be collected from two groups of neutropenic patients in the case that a therapy with either meropenem or piperacillin/tazobactam is needed due to a suspected infection. The intestinal resistome will be determined and quantified using shotgun metagenomics. Based on this, regression models will be used to determine the actual selection pressure caused by these drugs, and both selective forces will be compared. The results will reveal if there is a drug that causes a lower selection pressure compared to the other. The study aims to generate knowledge that is required to design effective antibiotic stewardship programs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03140826
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of meropenem
Trials testing the same drug.
- NCT05042271 — PK of Meropenem in Patients on Plasma Exchange · unknown
- NCT04402359 — Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS · completed
- NCT03182504 — A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants · Phase 1 · completed
- NCT02486627 — A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including · Phase 3 · completed
- NCT01970371 — A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae ( · Phase 3 · completed
Other University Hospital Tuebingen trials
Trials by the same sponsor.
- NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
- NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
- NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
- NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
- NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03140826 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
- Last refreshed: 3 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03140826.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing